CQ9[电子中国]官方网站

NOTIFICATION OF BOARD MEETING

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025

VOLUNTARY ANNOUNCEMENT - LM-299 OUT-LICENSING COLLABORATION PROGRESSING SMOOTHLY; US$300 MILLION MILESTONE PAYMENT TO BE RECEIVED SHORTLY

VOLUNTARY ANNOUNCEMENT - IND APPROVAL FOR LM-350 "CDH17 ADC" FROM THE US FDA

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION FULL ACQUISITION OF LANOVA MEDICINES

VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST SUBJECT DOSING OF CLASS 1 INNOVATIVE DRUG TQB6411 (EGFR/c-MET BISPECIFIC ADC)

DISCLOSEABLE TRANSACTION - FULL ACQUISITION OF LANOVA MEDICINES

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF CULMERCICLIB CAPSULE FOR FIRST-LINE TREATMENT OF BREAST CANCER